EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes

Lijuan Wang, Ines Mesa-Eguiagaray, Harry Campbell, James F Wilson, Veronique Vitart, Xue Li, Evropi Theodoratou

European Journal of Epidemiology · 2024-08 · 39 (8) · 869-880

DOI: 10.1007/s10654-024-01138-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Epidemiology, online erschienen am 11.07.2024. Verfasst von Lijuan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Uric Acid, Cardiovascular Diseases, Drug Repositioning. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK Career Development Fellowship, MRC University Unit Transition Program grant, Natural Science Fund for Distinguished Young Scholars of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uric acid has been linked to various disease outcomes. However, it remains unclear whether uric acid-lowering therapy could be repurposed as a treatment for conditions other than gout. We first performed both observational phenome-wide association study (Obs-PheWAS) and polygenic risk score PheWAS (PRS-PheWAS) to identify associations of uric acid levels with a wide range of disease outcomes. Then, trajectory analysis was conducted to explore temporal progression patterns of the observed disease outcomes. Finally, we investigated whether uric acid-lowering drugs could be repurposed using a factorial Mendelian randomization (MR) study design. A total of 41 overlapping phenotypes associated with uric acid levels were identified by both Obs- and PRS- PheWASs, primarily cardiometabolic diseases. The trajectory analysis illustrated how elevated uric acid levels contribute to cardiometabolic diseases, and finally death. Meanwhile, we found that uric acid-lowering drugs exerted a protective role in reducing the risk of coronary atherosclerosis (OR = 0.96, 95%CI: 0.93, 1.00, P = 0.049), congestive heart failure (OR = 0.64, 95%CI: 0.42, 0.99, P = 0.043), occlusion of cerebral arteries (OR = 0.93, 95%CI: 0.87, 1.00, P = 0.044) and peripheral vascular disease (OR = 0.60, 95%CI: 0.38, 0.94, P = 0.025). Furthermore, the combination of uric acid-lowering therapy (e.g. xanthine oxidase inhibitors) with antihypertensive treatment (e.g. calcium channel blockers) exerted additive effects and was associated with a 6%, 8%, 8%, 10% reduction in risk of coronary atherosclerosis, heart failure, occlusion of cerebral arteries and peripheral vascular disease, respectively. Our findings support a role of elevated uric acid levels in advancing cardiovascular dysfunction and identify potential repurposing opportunities for uric acid-lowering drugs in cardiovascular treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mendelian Randomization AnalysisUric AcidCardiovascular DiseasesDrug RepositioningHumansPhenomicsGenome-Wide Association StudyPhenotypeMaleFemale

Stichwörter der Autor:innen

Cardiovascular diseaseDrug repurposingFactorial Mendelian randomizationPhenome-wide association studyUric acid

Substanzen

Uric Acid

Autor:innen und Institutionen

  • Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK.
  • MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
  • School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK. e.theodoratou@ed.ac.uk.
  • Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK. e.theodoratou@ed.ac.uk.

Förderung

  • Cancer Research UK Career Development Fellowship
  • MRC University Unit Transition Program grant
  • Natural Science Fund for Distinguished Young Scholars of Zhejiang Province
  • Darwin Trust of Edinburgh
  • National Nature Science Foundation of China
  • Medical Research Council

Zitieren

APA

Wang, L., Mesa-Eguiagaray, I., Campbell, H., Wilson, J. F., Vitart, V., Li, X., & Theodoratou, E. (2024). A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes. European Journal of Epidemiology, 39(8), 869-880. https://doi.org/10.1007/s10654-024-01138-0

Vancouver

Wang L, Mesa-Eguiagaray I, Campbell H, Wilson JF, Vitart V, Li X, et al. A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes. European Journal of Epidemiology. 2024;39(8):869-880. doi:10.1007/s10654-024-01138-0

BibTeX
@article{Wang2024,
  author = {Wang, Lijuan and Mesa-Eguiagaray, Ines and Campbell, Harry and Wilson, James F and Vitart, Veronique and Li, Xue and Theodoratou, Evropi},
  title = {A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes},
  journal = {European Journal of Epidemiology},
  year = {2024},
  volume = {39},
  number = {8},
  pages = {869--880},
  doi = {10.1007/s10654-024-01138-0}
}
Kostenlos starten →